Canada needs its rare disease strategy to get the health-care system back on track

Only 65 per cent of rare disease treatments make it to Canada. Health-care workers in the rare disease field, and their patients, need a light at the end of the tunnel.

Health Minister Jean-Yves Duclos’ mandate letter from the prime minister directs him to move forward on a national strategy on high-cost drugs for rare diseases. The Hill Times photograph by Andrew Meade

Opinion

BY CHRISTIAN HANSEN

October 5, 2022

It has been a year since I left Europe to lead Alexion AstraZeneca Rare Disease’s operations in Canada. During this time, I have immersed myself in the country’s complex health-care and rare disease operating environment, seeing real progress being made, even as the resiliency and sustainability...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy